ARTICLE | Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

September 8, 2017 12:23 AM UTC

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $0.81 (12%) to $7.55 Thursday after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exercised a 2014 option for exclusive rights to Adaptimmune’s NY-ESO SPEAR T cell therapy program. The decision comes as Adaptimmune was preparing for a pivotal trial of the product to treat synovial sarcoma.

The product comprises autologous T cells genetically modified to express T cell receptors (TCR) targeting cancer/testis antigen 1B (NY-ESO-1; CTAG1B). Prior to the transition, the product was in clinical trials to treat sarcoma, non-small cell lung cancer (NSCLC), ovarian cancer and multiple myeloma. ...